Jove
Visualize
Contact Us

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  2. Effect Of Screening On Ovarian Cancer Mortality: The Prostate, Lung, Colorectal And Ovarian (plco) Cancer Screening Randomized Controlled Trial.
  1. Home
  2. Effect Of Screening On Ovarian Cancer Mortality: The Prostate, Lung, Colorectal And Ovarian (plco) Cancer Screening Randomized Controlled Trial.

Related Experiment Video

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening

Saundra S Buys1, Edward Partridge, Amanda Black

  • 1Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, USA.

JAMA
|June 7, 2011

View abstract on PubMed

Summary
This summary is machine-generated.

Annual screening for ovarian cancer using CA-125 and transvaginal ultrasound did not reduce mortality in the general US population. False-positive screening results led to complications from diagnostic procedures.

Related Experiment Videos

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Preventive Medicine

Background:

  • Ovarian cancer screening using cancer antigen 125 (CA-125) and transvaginal ultrasound has an unclear impact on mortality.
  • The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial aimed to clarify this effect.

Purpose of the Study:

  • To evaluate the impact of ovarian cancer screening on mortality within the PLCO Cancer Screening Trial.
  • To assess secondary outcomes including ovarian cancer incidence and complications.

Main Methods:

  • A randomized controlled trial involving 78,216 women aged 55-74 years.
  • Intervention group received annual CA-125 screening for 6 years and transvaginal ultrasound for 4 years.
  • Usual care group received standard medical care without annual screening; follow-up for up to 13 years.

Main Results:

  • Ovarian cancer incidence was slightly higher in the screening group (5.7 vs. 4.7 per 10,000 person-years).
  • Ovarian cancer mortality showed no significant reduction (RR, 1.18; 95% CI, 0.82-1.71).
  • 15% of women with false-positive results experienced serious complications from surgical follow-up.

Conclusions:

  • Simultaneous screening with CA-125 and transvaginal ultrasound did not decrease ovarian cancer mortality in the general US population.
  • Diagnostic evaluation following false-positive screening results was associated with complications.
  • Further research may be needed to identify effective ovarian cancer screening strategies.